News
-
News
08 October 2018
Ovarian Cancer Action Research Grant Award Ceremony
Last night the Ovarian Cancer Action Research Grant Awards took place at the Royal Society, awarding funds to scientists working to tackle the disease at every level – from screening and early detection to treatment and recurrence.
-
News
13 September 2018
Cancer patients in Northern Ireland set to have same access to drugs as the rest of the UK
Cancer patients in Northern Ireland are set to have the same access to drugs as the rest of the UK, the Department of Health has announced.
-
News
12 September 2018
Comment regarding potential urine test for ovarian cancer
Yesterday it was reported that a new urine test for ovarian cancer was on the horizon. We take a closer look at the story.
-
News
03 September 2018
Call for equal access to Niraparib for women in Northern Ireland
This year the PARP inhibitor Niraparib has been approved for use throughout much of the UK, giving hope to thousands of women with recurrent, platinum-sensitive ovarian cancer. However, it is not yet available in Northern Ireland.
-
News
24 August 2018
Drug combination shows exciting results in ovarian cancer in early trial
A study published recently in the Annals of Oncology and reported by the Institute of Cancer Research has shown exciting results that could offer hope to thousands of women with recurrent, platinum-resistant advanced stage ovarian cancer.
-
News
23 August 2018
First ever NHS ovarian cancer early detection pilot announced
Ovarian Cancer Action is pleased to support the ALDO project; a pilot launched by The UCLH Cancer Collaborative, which aims to establish whether ovarian cancer screening can be feasible and cost effective on the NHS for women with BRCA1 and BRCA2 mutations.
-
News
13 August 2018
Exciting new research could lead to personalised ovarian cancer treatments
Patterns of genetic mutation in ovarian cancer are helping make sense of the disease and could be used to personalise treatment in future, according to a study published in Nature Genetics today.
-
News
10 August 2018
Innovative new treatment approved for Scottish ovarian cancer patients
The Scottish Medicine Consortium (SMC) has today approved a drug called Niraparib, providing new hope for women with...
-
News
26 July 2018
Could regular aspirin use reduce ovarian cancer risk?
There have been a series of reports recently claiming that taking aspirin can play a major role in both preventing ovarian cancer and increasing survival rates in women who already have the disease.
-
News
25 July 2018
10,000 signatures and counting — we did it!
Over the past few months, thousands of you have signed and shared the petition to the UK Government to fund a national clinical audit for ovarian cancer. Thanks to you, the petition has now reached 10,000 signatures, meaning we can expect a government response in due course.
-
News
10 July 2018
Allyson Kaye to step down as Chair after 13 years
After 13 years as Chair of Ovarian Cancer Action, Allyson Kaye MBE has announced her decision to step down. We are delighted that Allyson will continue her close connection with the charity in her new role of President, acting as an advisor and ambassador. Our current Vice-Chair, Dr Wayne Phillips has been appointed in her stead and Allyson will work closely with Wayne and the board as they embark on an exciting new chapter for the charity.
-
News
28 June 2018
More women could be eligible for groundbreaking ovarian cancer drug
The Telegraph has reported today that the latest trials of the drug Olaparib (Lynparza) have produced results that could make it accessible for a significantly increased number of women with advanced stage ovarian cancer.
-
News
20 June 2018
Ovarian Cancer Action receives £150,000 at NEX Giving Day
Ovarian Cancer Action was honoured to have been nominated as one of the six chosen charities for the first NEX Giving Day, held in London on 7th June.
-
News
15 June 2018
Ovarian Cancer Action scientists discover mechanism that ‘deactivates’ ovarian cancer cells
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells, which could lead to better treatments for women with ovarian cancer.
-
News
10 June 2018
Ovarian Cancer Action launches Hereditary Cancer Risk Tool
This week sees the launch of Ovarian Cancer Action's Hereditary Cancer Risk Tool, which has been developed to help people identify their cancer risk. We believe everyone has the right to understand if their family history puts them at risk of ovarian and other cancers, as well as the risk-reducing options available.
-
News
01 June 2018
Ovarian cancer drug Niraparib approved for NHS use
The National Institute for Health and Care Excellence (NICE) have today announced that a new drug, Niraparib, has been recommended for use in the Cancer Drugs Fund as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer.
-
News
01 June 2018
'Breakthrough' blood test could detect ovarian cancer in its earliest stages
In today’s news, a blood test has been hailed a ‘possible holy grail’ in the early detection of ovarian cancer. The...
-
News
30 May 2018
What is patient data and how can it help cancer research?
This month marks a big change in health services as the NHS introduces a new national data opt-out service to give patients more control over how their personal information is used. We take a look at the new system and how data acts as a powerful tool in cancer research.
-
News
22 May 2018
Artificial intelligence to improve cancer diagnosis
Ovarian Cancer Action welcomes today’s announcement from the Prime Minister to use emerging technologies to transform cancer diagnosis in the UK, saving around 22,000 lives a year by 2033.
-
News
15 May 2018
Scientists identify cause of resistance to ovarian and breast cancer drug
Scientists at the Institute of Cancer Research have identified a genetic mutation that causes cancer cells to become resistant to PARP inhibitors, such as olaparib, which are used to treat ovarian and breast cancers.